Core Insights - Akoya Biosciences and Enable Medicine have announced a collaboration to create the largest commercially available single-cell spatial proteomics atlas, which includes over 100 million single cells from more than 8,500 samples across 15+ cancer types [1][2][3] Group 1: Enable Pan-Cancer Atlas Features - The Enable Atlas is a multi-modal dataset built using Akoya's PhenoCycler-Fusion platform, featuring the PhenoCode™ Discovery IO60 panel as foundational data [2] - It includes rich cellular features with up to 60 protein biomarkers, H&E images, spatial transcriptomics measurements, and comprehensive clinical metadata [2][5] - The dataset is curated, standardized, and commercially licensable, providing immediate value to biopharma researchers and AI model developers [3][5] Group 2: Benefits for Biopharma and Research - The Enable Atlas allows biopharma customers to generate new hypotheses, increase statistical power, and identify novel cellular phenotypes at an unprecedented scale [4] - It is designed for discovery and offers unmatched scale and depth with over 100 million spatially profiled single cells [8] - The dataset's analytical capabilities enable biomarker discovery, comparative analysis, and statistical validation in both discovery and translational research [5][6] Group 3: Upcoming Showcase - The Enable Atlas will be showcased at the American Association for Cancer Research (AACR) Annual Meeting, providing attendees with a first look at this new spatial proteomics resource [8][9] - A live demonstration will be available during the event, with team members present to discuss applications in translational research, biomarker discovery, and drug development [9]

MARLBOROUGH, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced a collaboration with the Singapore Translational Cancer Consortium (STCC) on the STCC Unified PD1/PDL1 Evaluation of Response (SUPER) study. This initiative aims to identify and validate key biomarkers predicting response or refractoriness to immune checkpoint inhibitors using Akoya's IO60 panel for spatial proteomic analysis. Advancing Precision Immunotherapy ...